Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFNB40)

Drug Name

Noradrenalone (arterenone) Drug Info

Synonyms

Arterenone; 499-61-6; Noradrenalone; 2-Amino-1-(3,4-dihydroxyphenyl)ethanone; 2-Amino-1-(3,4-dihydroxyphenyl)ethan-1-one; Arterenon; EINECS 207-883-3; U 0603; 2-Amino-3',4'-dihydroxyacetophenone; BRN 2719260; Ethanone, 2-amino-1-(3,4-dihydroxyphenyl)-; ACETOPHENONE, 2-AMINO-3',4'-DIHYDROXY-; ADROLOP; AC1Q5DI7; SCHEMBL1703207; AC1L1V18; CTK4J1837; 5090-29-9 (hydrochloride); DTXSID10198144; MolPort-001-785-861; ZINC37629258; AKOS006275024; ACN-049173; AS07040; LS-13364; KB-282798; KB-227300; Ethanone,2-amino-1-(3,4-dihydroxyphenyl)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10359
CAS Number: CAS 499-61-6
TTD Drug ID: DMFNB40

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aromatic-L-amino-acid decarboxylase (DDC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B6	DMDBZMV	Vitamin B6 deficiency	5B5D	Approved	[2]
Carbidopa	DMHRG8Q	Parkinson disease	8A00.0	Approved	[3]
Patrome	DM3H2U4	Parkinson disease	8A00.0	Phase 3	[4]
Benserazide	DMLU8NX	N. A.	N. A.	Phase 3	[3]
AV-201	DMDL9WU	Parkinson disease	8A00.0	Phase 2	[5]
VY-AADC	DMPSBTL	Parkinson disease	8A00.0	Phase 2	[6]
GT-AADC	DM8N3OQ	Aromatic L-amino acid decarboxylase deficiency	5C59.00	Phase 2	[7]
PTC-AADC	DM9ZHE3	Aromatic L-amino acid decarboxylase deficiency	5C59.00	Phase 2	[8]
ProSavin	DMJ42E6	Parkinson disease	8A00.0	Phase 1/2	[9]
OXB-102	DMXF9DM	Parkinson disease	8A00.0	Phase 1/2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatic-L-amino-acid decarboxylase (DDC)	TTN451K	DDC_HUMAN	Activator	[1]

------------------------------------------------------------------------------------

References

1	Activation of an adrenergic pro-drug through sequential stereoselective action of tandem target enzymes. Biochem Biophys Res Commun. 1992 Nov 30;189(1):33-9.
2	Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4.
3	Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22.
4	The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72.
5	UCSF report
6	Clinical pipeline report, company report or official report of Voyager Therapeutics.
7	Clinical pipeline report, company report or official report of PTC Therapeutics.
8	ClinicalTrials.gov (NCT04903288) An Open-Label Trial to Address the Safety of the SmartFlow MR-Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Subjects. U.S.National Institutes of Health.
9	Clinical pipeline report, company report or official report of Oxford BioMedica.
10	Clinical pipeline report, company report or official report of Oxford BioMedica.